Remi Meds Review
Best for: Buyers wanting a per-dose-tier compounded-GLP-1 platform with a NAMED compounding pharmacy partner (Strive Pharmacy, Gilbert AZ) and explicit 503A compliance language, who can accept a third-party clinical-network model (Beluga Health) and no public per-state availability list.
Remi Meds (remimeds.com) is a California-corporation DTC compounded-GLP-1 telehealth platform operated by T-C HEALTH CO (dba Remi Meds), with corporate mailing at 920 E. Dixie Ave. Suite A, Leesburg, FL 34748. The product line is compounded semaglutide (injection) priced from $249/mo (0.25mg) to $369/mo (2.4mg) and compounded tirzepatide-with-B12 (injection) priced from $349/mo (2.25mg) to $639/mo (11.25mg), plus ancillary NAD+, Sermorelin, and Glutathione (both injection and troche forms for the non-GLP-1 ancillaries). Clinical services are delivered by Beluga Health, an independent third-party physician network. Pharmacy fulfillment is named explicitly: Strive Pharmacy (Gilbert, AZ). LegitScript verification badge displayed on site (independent merchant-ID lookup pending). Tirzepatide product page cites verbatim ‘503A of the Federal Food, Drug, and Cosmetic Act’ compounding compliance and explicit non-affiliation with Eli Lilly. The site does NOT sell retatrutide (verified May 2026, consistent with the FDA September 2025 enforcement sweep). ‘Nationwide service’ claim with no per-state availability list. No named medical director, founder, or physician on the public site. No insurance accepted. Returns/refunds policy verbatim: ‘Due to federal and state law, medications cannot be returned. All sales are final.’ Live-verified 2026-05-24. NOTE: not to be confused with Remedy Meds (remedymeds.com) — a separate entity that DID receive FDA Warning Letter 716830 on 2025-09-09.
Medium confidence · Last verified 2026-05-24 via Eli Marsden · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Remi Meds is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Remi Meds prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| 0.25mg starting | compounded injection | $249 |
| 2.4mg maintenance | compounded injection | $369 |
| 2.25mg starting | compounded injection | $349 |
| 11.25mg maintenance | compounded injection | $639 |
✓ Pros
- •**Named compounding pharmacy** (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers who only say ‘503A pharmacies’
- •**LegitScript verification badge** present on homepage
- •**Verbatim 503A FDCA compliance language** on tirzepatide product page
- •**Per-dose-tier pricing fully surfaced** (no ‘as low as’ floor-only obfuscation)
- •Operating corporate entity disclosed (T-C HEALTH CO, California dba)
- •Does NOT sell retatrutide (compliant with FDA Sept 2025 enforcement landscape)
- •Clear non-affiliation disclaimer re: Wegovy/Ozempic/Mounjaro/Saxenda/Victoza trademarks
✗ Cons
- •**No named medical leadership** — no Medical Director, founder, or physician disclosed on any public page
- •**States served NOT enumerated** — ‘nationwide’ claim with no per-state list
- •**Third-party clinical network (Beluga Health)** flagged in March 2026 StatNews analysis as one of four medical groups affiliated with 30%+ of FDA-warned GLP-1 telehealth companies (Remi Meds itself NOT named in any FDA warning letter)
- •**Year founded / corporate history opaque**
- •Two different phone numbers and a secondary email (info@rekindlerx.com) hint at affiliated ‘Rekindle RX’ brand sharing infrastructure
- •Mailing address (Leesburg FL) does not match operating-entity state (California)
- •No SOC 2 claim; HIPAA Notice present but no third-party attestation
Ready to start with Remi Meds?
Starting at $249/month. See current pricing and start your free consultation.
Sources & methodology
Our Remi Meds review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Remi Meds
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Remi Meds?
Starting at $249/month. See current pricing and start your free consultation.